The invention provides a method for treating a subject suffering from early stage Parkinson's disease with a pharmaceutical formulation containing an olive polyphenol composition. The olive polyphenol composition includes hydroxytyrosol and at least one additional olive polyphenol, and the hydroxytyrosol represents about 40 wt. % to about 90 wt. % of the olive polyphenol composition. The formulation is administered to the subject within the context of a dosing regimen that provides a daily dosage of the olive polyphenol composition in the range of 30 mg to about 2500 mg. The invention additionally provides a method for reducing the dose of an antiparkinsonism drug used in the treatment of early stage Parkinson's disease, as well as a pharmaceutical formulation for treating early stage Parkinson's disease.

The invention provides a method for treating a subject suffering from early stage Parkinson's disease with a pharmaceutical formulation containing an olive polyphenol composition. The olive polyphenol composition includes hydroxytyrosol and at least one additional olive polyphenol, and the hydroxytyrosol represents about 40 wt. % to about 90 wt. % of the olive polyphenol composition. The formulation is administered to the subject within the context of a dosing regimen that provides a daily dosage of the olive polyphenol composition in the range of 30 mg to about 2500 mg. The invention additionally provides a method for reducing the dose of an antiparkinsonism drug used in the treatment of early stage Parkinson's disease, as well as a pharmaceutical formulation for treating early stage Parkinson's disease.

The invention provides a method for treating a subject suffering from early stage Parkinson's disease with a pharmaceutical formulation containing an olive polyphenol composition. The olive polyphenol composition includes hydroxytyrosol and at least one additional olive polyphenol, and the hydroxytyrosol represents about 40 wt. % to about 90 wt. % of the olive polyphenol composition. The formulation is administered to the subject within the context of a dosing regimen that provides a daily dosage of the olive polyphenol composition in the range of 30 mg to about 2500 mg. The invention additionally provides a method for reducing the dose of an antiparkinsonism drug used in the treatment of early stage Parkinson's disease, as well as a pharmaceutical formulation for treating early stage Parkinson's disease.

A plant derived active ingredient and a cosmetic and a drug composition including the plant derived ingredient including: an extract from at least one plant of the gender Olea, an extract from at least one plant of the gender Tilia and/or an extract from at least one plant of the gender Cydonia.

A plant derived active ingredient and a cosmetic and a drug composition including the plant derived ingredient including: an extract from at least one plant of the gender Olea, an extract from at least one plant of the gender Tilia and/or an extract from at least one plant of the gender Cydonia.

A plant derived active ingredient and a cosmetic and a drug composition including the plant derived ingredient including: an extract from at least one plant of the gender Olea, an extract from at least one plant of the gender Tilia and/or an extract from at least one plant of the gender Cydonia.

The present invention is directed to a method for preparing plant extracts comprising the steps of (i) preparing a soluble extract from (a) plants or parts thereof and (b) an aqueous, alcoholic or aqueous alcoholic mixed extractant; and removal of insoluble components, (ii) concentrating the extract to a dry substance content at which the contained lipids and lipoids form suspended and/or emulgated aggregates, (iii) separating the suspended and/or emulgated aggregates by microfiltration from the concentrated extract, and (iv) optionally removing the extractant. The invention further pertains to an extract and composition comprising said extract as prepared by this method.

The present invention is directed to a method for preparing plant extracts comprising the steps of (i) preparing a soluble extract from (a) plants or parts thereof and (b) an aqueous, alcoholic or aqueous alcoholic mixed extractant; and removal of insoluble components, (ii) concentrating the extract to a dry substance content at which the contained lipids and lipoids form suspended and/or emulgated aggregates, (iii) separating the suspended and/or emulgated aggregates by microfiltration from the concentrated extract, and (iv) optionally removing the extractant. The invention further pertains to an extract and composition comprising said extract as prepared by this method.

A composition contains at least one of homovanillyl alcohol (HVA) or its previously unidentified isomer (isoHVA). Additionally or alternatively, the composition contains a precursor of HVA and/or isoHVA (e.g., hydroxytyrosol, oleuropein aglycone, oleuropein, demethyloleuropein, oleuroside, verbascoside or mixtures thereof) and also contains at least one probiotic and/or at least one enzyme which convert the precursor to HVA and/or isoHVA in vivo (and/or an intermediate compound then subjected to methylation in vivo to form HVA and/or isoHVA). The composition can be administered to an individual to treat or reduce incidence of impaired mobility in an older adult; stimulate bone formation and/or inhibit bone resorption; treat or reduce incidence of synovitis in an individual in need or at risk thereof; treat or reduce incidence of articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or treat or reduce incidence of cartilage breakdown.

A composition contains at least one of homovanillyl alcohol (HVA) or its previously unidentified isomer (isoHVA). Additionally or alternatively, the composition contains a precursor of HVA and/or isoHVA (e.g., hydroxytyrosol, oleuropein aglycone, oleuropein, demethyloleuropein, oleuroside, verbascoside or mixtures thereof) and also contains at least one probiotic and/or at least one enzyme which convert the precursor to HVA and/or isoHVA in vivo (and/or an intermediate compound then subjected to methylation in vivo to form HVA and/or isoHVA). The composition can be administered to an individual to treat or reduce incidence of impaired mobility in an older adult; stimulate bone formation and/or inhibit bone resorption; treat or reduce incidence of synovitis in an individual in need or at risk thereof; treat or reduce incidence of articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or treat or reduce incidence of cartilage breakdown.